{"disease":{"id":"vulvar-hsil","name":"vulvar hsil"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06052696","title":"Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSIL","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT03180684","title":"Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Inovio Pharmaceuticals","has_results":true},{"nct_id":"NCT03937791","title":"Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}